Hoosiers Work for Health

June is Alzheimer's & Brain Awareness Month. Over 7 million Americans are living with Alzheimer’s, and nearly 13 million serve as their caregivers. Two-thirds of Americans have at least one major potential risk factor for dementia.

While there is currently no cure for Alzheimer’s, we are at a turning point in what we know about brain health.Science shows us that positive actions can make a real difference helping to reduce the risk of cognitive decline and protect brain health. It’s never too early or too late.

Take the (re)think your brain 6-Step Challenge, a step-by-step guide to help you take charge of your brain health. Sign up today at rethinkyourbrain.org. https://www.alz.org/rethink-your-brain

(re)think your brain™ | 6 Steps to Better Brain Health | alz.org Discover 6 science-backed steps to support brain health and protect your memory and thinking — tips on exercise, diet, sleep & more. Get started now.

CHECK THIS OUT: Fox Business reports the federal 340B Drug Pricing Program is facing allegations of fraud and hospital profiteering, with critics warning low-income patients are being left behind while healthcare systems reap billions.

Hospitals accused of cashing in on discount drugs in MASSIVE fraud scandal FOX Business’ Gerri Willis reports the federal 340B Drug Pricing Pr...

Making prescription drugs more accessible and affordable sounds great in theory, but everyone seems to have different ideas on how to make that happen. Adina Lasser, director of public policy and government relations for Alliance for Aging Research, breaks down the complex landscape of federal drug pricing policy with Medical Economics and what patients and physicians need to know.

Access, affordability, ambiguity: Who really benefits from federal prescription drug price policies? | Medical Economics A policy expert explains what physicians need to know when patients ask about the changing prices of their medicines.

"If a charity organization collected billions of dollars with little evidence that needy people benefited, regulators and the public would quickly demand answers.
Yet many large hospital systems participating in the federal 340B Drug Pricing Program are quietly doing just that—extracting billions in drug discounts with scarce oversight and no obligation to prove vulnerable patients benefit."

-Sally Pipes, President, CEO, Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute

It’s Time For Congress To Get 340B Out Of Its Blind Spot When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

European experts are not speaking hypothetically. As director of the Austrian Economics Center and a member of Austria’s National Council, Barbara Kolm has direct experience with the European drug pricing systems some want the U.S. to adopt. Her warning about the risks to innovation and future cures should not be taken lightly.

Don’t follow us into ‘most-favored-nation’ drug pricing Today, medical leaps that once took decades are now happening in months.

For families managing serious or chronic conditions, copay assistance can mean the difference between getting treatment or going without it.

Indiana’s new patient-first laws help ensure those savings actually reach patients instead of being absorbed by insurance companies and pharmacy benefit managers. National Kidney Foundation of Indiana CEO Liz Ellis explains why these reforms matter for Hoosier families.

Lawmakers working to ensure that insurance works for patients Indiana lawmakers have taken bold steps to put patients ahead of harmful insurance practices. Hoosier patients, not insurance giants, should start benefiting at the pharmacy counter.

Programs designed to support rural healthcare should benefit rural communities, not large, urban hospital systems exploiting loopholes.

A new study examining Medicare “dual classification” adds to growing concerns about transparency and accountability in programs like 340B. In a new piece from the Goshen News, Indiana State Grange President Jason Smith weighs in on what’s at stake for rural Hoosiers.

OP-ED: Protect rural health care for Hoosiers Rural Hoosiers have a simple way of life. My neighbors and fellow Grange members prefer it that way, but that doesn’t mean they should have to sacrifice access to quality

A federal judge's ruling on a North Dakota 340B law is shining a light on what has become one of healthcare’s biggest loopholes.

Hospitals acquire drugs at steep discounts and contract pharmacies profit while patients often see no savings at all.

The Wall Street Journal Editorial Board says policymakers can no longer ignore the problem.

The Great 340B Healthcare Grift A federal judge shows how this hospital ‘discount’ fleeces drug makers and patients.

A safety net program should protect patients, not leave them drowning in medical debt.

A new analysis highlights concerns that some 340B hospitals continue aggressive debt collection practices despite receiving major federal drug discounts.

Patients deserve clarity on how 340B dollars are being used to help them.

340B Hospitals Need Transparency, Not Blank Checks NCL finds many 340B hospitals more aggressive on medical debt, raising patient protection concerns.

Senator Todd Young recently sat down with the Making Medicine Podcast to discuss the growing risks of relying on China for critical biotech inputs, the urgent need for faster and more predictable FDA processes and the policies required to keep the United States competitive in a rapidly evolving global landscape.

From supply chain vulnerabilities to the rise of AI-driven drug development, this discussion highlights how innovation, policy and national defense are increasingly intertwined. Senator Young also weighs in on drug pricing, biotech investment and why strengthening the entire ecosystem from startups to large-scale manufacturers is essential for long-term leadership.

Listen to the full podcast on YouTube: https://www.youtube.com/watch?v=JZOpM8usxaI